Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis
David M P De Oliveira 1, Lisa Bohlmann 1, Trent Conroy 2, Freda E-C Jen 2, Arun Everest-Dass 2, Karl A Hansford 3, Raghu Bolisetti 3, Ibrahim M El-Deeb 2, Brian M Forde 1 4, Minh-Duy Phan 1, Jake A Lacey 5, Aimee Tan 5, Tania Rivera-Hernandez 1 6, Stephan Brouwer 1, Nadia Keller 1, Timothy J Kidd 1, Amanda J Cork 1, Michelle J Bauer 4, Gregory M Cook 7, Mark R Davies 5, Scott A Beatson 1, David L Paterson 4, Alastair G McEwan 1, Jian Li 8, Mark A Schembri 1, Mark A T Blaskovich 3, Michael P Jennings 2, Christopher A McDevitt 5, Mark von Itzstein 2, Mark J Walker 9AffiliationsDOI: 10.1126/scitranslmed.abb3791
- PMID: 33208501
Abstract
The emergence of polymyxin resistance in carbapenem-resistant and extended-spectrum β-lactamase (ESBL)-producing bacteria is a critical threat to human health, and alternative treatment strategies are urgently required. We investigated the ability of the hydroxyquinoline analog ionophore PBT2 to restore antibiotic sensitivity in polymyxin-resistant, ESBL-producing, carbapenem-resistant Gram-negative human pathogens. PBT2 resensitized Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa to last-resort polymyxin class antibiotics, including the less toxic next-generation polymyxin derivative FADDI-287, in vitro. We were unable to select for mutants resistant to PBT2 + FADDI-287 in polymyxin-resistant E. coli containing a plasmid-borne mcr-1 gene or K. pneumoniae carrying a chromosomal mgrB mutation. Using a highly invasive K. pneumoniae strain engineered for polymyxin resistance through mgrB mutation, we successfully demonstrated the efficacy of PBT2 + polymyxin (colistin or FADDI-287) for the treatment of Gram-negative sepsis in immunocompetent mice. In comparison to polymyxin alone, the combination of PBT2 + polymyxin improved survival and reduced bacterial dissemination to the lungs and spleen of infected mice. These data present a treatment modality to break antibiotic resistance in high-priority polymyxin-resistant Gram-negative pathogens.
- Forums
- ASX - By Stock
- PBT2 further development!
Sci Transl Med. 2020 Nov 18;12(570):eabb3791. doi:...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.4¢ | $236 | 48.28K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
61 | 70188651 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 29680389 | 23 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
61 | 70188651 | 0.004 |
48 | 47138652 | 0.003 |
18 | 41489402 | 0.002 |
14 | 93470101 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 29680389 | 23 |
0.006 | 34293249 | 14 |
0.007 | 17470649 | 16 |
0.008 | 14399594 | 14 |
0.009 | 6000000 | 5 |
Last trade - 14.06pm 10/07/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online